Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Perceptive Capital Solutions (NASDAQ:PCSC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.
Valuation & Earnings
This table compares Neuphoria Therapeutics and Perceptive Capital Solutions”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | -$13,267.00 | -1,609.24 | -$370,000.00 | ($11.06) | -0.36 |
| Perceptive Capital Solutions | N/A | N/A | $840,000.00 | ($0.06) | -199.17 |
Institutional & Insider Ownership
15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 22.1% of Perceptive Capital Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings for Neuphoria Therapeutics and Perceptive Capital Solutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
| Perceptive Capital Solutions | 1 | 0 | 0 | 0 | 1.00 |
Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 431.65%. Given Neuphoria Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Perceptive Capital Solutions.
Profitability
This table compares Neuphoria Therapeutics and Perceptive Capital Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -76.93% | -54.76% |
| Perceptive Capital Solutions | N/A | -2.70% | -0.84% |
Risk & Volatility
Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Perceptive Capital Solutions has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
About Perceptive Capital Solutions
Perceptive Capital Solutions Corp is a blank check company. It formed for the purpose of entering into a combination with one or more businesses or entities. Perceptive Capital Solutions Corp is based in NEW YORK.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
